Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-

Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season- - Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038155

Enrollment

120000

Registered

2019-10-01

Start date

2019-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Families which had an IC (index case; the first patient diagnosed as influenza in each family) during the enrollment period (1 Oct 2018 - 23 Apr 2019) 2)Families whose IC was an outpatient 3)Families whose IC received baloxavir marboxil, oseltamivir, zanamivir or laninamivir on Day 1 (the first date when an IC was diagnosed as influenza).

Exclusion criteria

Exclusion criteria: 1)Families in which no family member was identified other than the IC 2)Families which had two or more ICs 3)Families whose IC was hospitalized after outpatient diagnosis 4)Families whose IC received several anti-influenza drugs

Design outcomes

Primary

Measure	Time frame
Occurrence of household influenza infection	—

Countries

Japan

Contacts

Public ContactMasakazu Notohara

Shionogi & Co., Ltd. Pharmacovigilance Department

masakazu.notohara@shionogi.co.jp+81-6-6209-6958

Outcome results